Faculty & Research
|Dr. Paula James - Program Director
Dr. Paula James is a Professor in the Department of Medicine, with cross-appointments to Pathology & Molecular Medicine and Pediatrics. She joined the Faculty in July of 2004 and is a Clinician Scientist with 75% protected time for research.
Dr. James is a Principal Investigator in the Clinical and Molecular Hemostasis Research Group at Queen’s University with an active basic and clinical research program investigating the genetic basis of inherited bleeding disorders as well as the quantitation of bleeding symptoms. Her group is comprised of post-doctoral fellows, graduate students and well as research associates. In recent years, activities have included validating and publishing the Condensed MCMDM-1VWD Bleeding Questionnaire, which has gained international recognition as well as optimizing a protocol for culturing BOEC (Blood Outgrowth Endothelial Cells) from patients with both inherited and acquired diseases. In May 2015, the Let’s Talk Period website and aligned social media accounts were launched to increase knowledge about abnormal bleeding.
In addition to her research activities, Dr. James is the Medical Director of the Southeastern Ontario Inherited Bleeding Disorders Program and its aligned Women and Bleeding Disorders Clinic. She was awarded “Researcher of the Year” by the National Hemophilia Foundation (US organization) in 2011, and the Mihran and Mary Basmajian Award for Excellence in Health Research by the Faculty of Health Sciences at Queen’s University in 2012.
|Dr. Stephen Vanner
Dr. Vanner received a undergraduate degree in Life Sciences and a concurrent MD and MSc degree from Queen’s University. After completing his Internal Medicine and Gastroenterology training at Queen’s and he carried out post doctoral research training in enteric neurophysiology at the Vollum Institute in Portland Oregon. Since returning to Queen’s University in 1991 he has been an attending staff in Gastroenterology at the Kingston General and Hotel Dieu Hospitals and cares for patients with gastrointestinal disorders in both the inpatient and outpatient departments. He performs a full range of endoscopic procedures including ERCP.
He has subspecialty expertise in gastrointestinal motility disorders involving the lower GI tract including the small intestine, colon and anorectum and is director of the anorectal motility laboratory.
He has an established translational research program that examines mechanisms underlying pain signaling and motility in the gastrointestinal tract.
|Dr. Mark Ormiston
When people think of the immune system, they usually focus on its ability to fight off infection and combat diseases such as cancer. Dr. Mark Ormiston is working to show that immune cells can serve other important functions, including the regulation of blood vessel integrity, growth and repair. Dr. Ormiston’s research focuses on pulmonary arterial hypertension (PAH), a deadly disease of the blood vessels in the lung that preferentially affects women in their 30s to 50s. Although commonly viewed as a vascular disease, PAH is often linked to autoimmunity and viral infections like HIV. Dr. Ormiston is investigating how impairment of a specific immune cell type, known as the Natural Killer (NK) cell, may be critical to disease development and could offer a new avenue for treatment. While traditionally known for their ability to eliminate viruses and cancer, NK cells have also been shown to regulate changes in uterine blood flow during pregnancy. By basing his work in these established roles for NK cells in pregnancy and cancer, Dr. Ormiston is investigating how similar processes can influence the structure of the lung vasculature in health and disease. The purpose of this research is to develop new immune-based treatments for PAH and other related vascular disorders. To this end, Dr. Ormiston is working on techniques to isolate and genetically modify patient stem cells, with the ultimate goal of creating tailored immune cell therapies that can reverse the vascular changes that devastate the lungs of PAH patients.
Learn more about Dr. Mark Ormiston
Dr. Gord Boyd
Dr. Boyd is currently working as a clinician-scientist in the Department of Medicine at Queen’s University, practicing both neurology and intensive care medicine. His translational research uses proteomic approaches to identify novel serum biomarkers that will help predict neurological recovery after critical illness, particularly cardiac arrest. His clinical research program uses non-invasive techniques, such as continuous electroencephalography, to monitor brain function in critically ill patients. He is interested in how brain function during critical illness correlates with long term neurological recovery among survivors of critical illness.
Dr. Rachel Holden
|Dr. Anne Ellis
Dr. Anne K. Ellis is a Professor in the Department of Medicine with a cross-appointment to the Department of Biomedical and Molecular Sciences at Queen’s University, having joined the Faculty in August 2008. Her position is one of a Clinician Scientist with 70% protected time for research.
She has served as the Chair of the Division of Allergy & Immunology since May 2010, and is the Director of the Allergy Research Unit at the Kingston Health and Science Center - Kingston General Hospital site. The flagship of this research program being the Environmental Exposure Unit (EEU), an internationally recognized and validated controlled allergen challenge model of allergic rhinitis. She also has gained considerable expertise in direct nasal allergen challenge and is a Principal Investigator within AllerGen NCE.
She additionally runs a basic science research program centered on the Kingston Allergy Birth Cohort study, a prospective birth cohort that has enrolled over 600 mother-child pairs to date, in order to study umbilical cord blood biomarkers that could be predictive of future atopic disease in childhood. Her interests and particular expertise lie in the evaluation of epigenetic modifications as they relate to atopic risk and also epigenetic changes that occur as a result of allergic inflammation.
|Dr. Don Maurice
The Maurice Lab is interested in investigating the role of cyclic nucleotide (cAMP and cGMP) compartmentation and cyclic nucleotide signaling in human vascular cells including arterial endothelial cells and arterial smooth muscle cells. Since virtually all cells are either directly or indirectly influenced by cAMP and or cGMP, this system represents a potential therapeutic target in multiple cardiovascular diseases such as atherosclerosis and restenosis, and is important processes such as angiogenesis.
Our laboratory investigates how signal compartmentation allows cAMP to regulate simultaneously myriad cellular events with specificity. Overall, our work shows that Cyclic Nucleotide Phosphodiesterase (PDEs), the sole enzymes that inactivate cAMP by hydrolysis, are critical for specificity in this system. In addition, while our studies demonstrate that PDEs are highly “druggable”, they also identify critical shortcoming in current targeting approaches. Specifically, although humans can generate >100 unique PDE variants, and PDEs are known to operate within unique cAMP signaling compartments in cells, current therapeutic strategies have failed to capitalize on their highly compartmented actions. Indeed, most approaches focus on findings agents that inhibit selected PDE activities by catalytic site inhibition without considering the hyper-localized nature of their actions (review Maurice et al., Nature Reviews, Drug Discovery, 13:290, 2014)1. The research elaborated here is a comprehensive plan to identify strategies that will allow inhibition of PDEs in their “natural environment” (i.e. in compartments) and to begin to translate these strategies into approaches to limit the mal-adaptive consequences of atherosclerosis and angiogenesis.
|Dr. Stephen Archer
Dr. Archer is a renowned cardiologist and physician scientist, accomplished author and dedicated educator. His research focus is on mechanism of oxygen sensing, mitochondrial biology and experimental therapeutics for pulmonary hypertension and cancer.
Having spent 12 years as a Chief of Cardiology at the University of Alberta and then at the University of Chicago, Dr. Archer returned to his medical school roots in 2012 to Queen’s University. He now serves as the Head of Medicine at Queen’s University, Hotel Dieu Hospital, Kingston General Hospital, and Providence Care. Directing a NIH- and CIHR-funded research lab, Dr. Archer and his associates study basic mechanisms of oxygen sensing in the vasculature and investigates the role of mitochondria, both as oxygen sensors and regulators of cell proliferation.
Dr. Archer’s clinical interests include pulmonary hypertension, persistent ductus arteriosus, strategies for improving cardiovascular care, and training the next generation of physician-scientists. He has published 200 papers and his translational cardiovascular research has been recognized with numerous awards, including being named the Chicago American Heart Association Coeur d’Or recipient for 2013.
|Dr. David Lillicrap
All of the research being undertaken by Dr. Lillicrap's group relates to molecular aspects of the hemostatic (coagulation) system. In the normal physiological state, a delicate balance is preserved between pro- and anti-coagulant factors that contributes to the maintenance of the normal circulation. When this balance is disrupted, bleeding or thrombosis occurs.
This research program utilizes the potential of molecular genetics and molecular biology to address a variety questions relating to pathological hemostasis. The studies range from an investigation of the mechanisms regulating production of the adhesive hemostatic protein, von Willebrand Factor, to the development of strategies for gene therapy for the inherited bleeding disease, hemophilia.
|Dr. Jennifer Flemming
Dr Jennifer Flemming joined the Faculty of Medicine at Queen’s University in 2014 as a member of the Division of Gastroenterology. She completed medical school at Dalhousie University (2006) and completed Internal Medicine (2009) and Gastroenterology training (2011) at Queen’s University. She then spent two years at the University of California San Francisco completing subspecialty training in Hepatology and Liver Transplantation as well as obtaining her Master’s Degree (MAS) in Advanced Clinical Research.
Dr. Flemming is a Southeastern Ontario Academic Medical Association (SEAMO) Clinician Scientist with 70% of her time protected for research activity. She is a member of the Cancer Care and Epidemiology (CCE) group at the Cancer Research Institute at Queen’s University with a cross appointment to the Department of Public Health Sciences. Her health services research program focuses on the epidemiology and natural history of cirrhosis, hepatitis C and primary liver cancers.
|Dr. Annette Hay
Dr. Annette Hay is a Hematologist within the Department of Medicine, Queen’s University, cross-appointed to the Departments of Oncology and Pediatrics, and a Senior Investigator with the Canadian Cancer Trials Group (CCTG).
Commencing at the University of Dundee (Sept 1996 – June 2001, MB ChB received July 2001), Dr. Hay completed her medical and hematology training in Scotland. In 2012 she undertook a 30 month Fellowship with the NCIC Clinical Trials Group (now CCTG), transitioning to a Senior Investigator role in 2014.
Dr. Hay’s clinical practice includes all areas of Hematology, with special interest in hematological malignancies. Clinics are held at the Cancer Center of Southeastern Ontario.
Dr. Hay’s specific research interests, delivered through collaboration with national and international investigators, include:
|Dr. Diane Lougheed
Dr. Lougheed is a Professor of Medicine in the Division of Respirology and currently holds the role of Divisional Chair. She is cross-appointed to the Department of Biomedical and Molecular Sciences (Physiology) and the Department of Public Health Sciences (Epidemiology). Additionally, she is an Adjunct Scientist at the Institute for Clinical Evaluative Sciences (ICES@Queen’s). She obtained her medical degree from McMasterUniversity, where she also completed Internal Medicine residency. She came to Queen’s in 1990 for respirology fellowship training and joined the faculty in 1993. She also holds a Master’s Degree in Epidemiology from Queen's University.
Dr. Lougheed is a clinician scientist whose primary clinical interests are asthma and cystic fibrosis in adults. She established an inter-disciplinary tertiary care Asthma Program locally, including an Asthma Education Centre, of which she is the Medical Director and the Asthma Research Unit at Kingston General Hospital. She is also the Director of the Adult Cystic Fibrosis Clinic at Hotel Dieu Hospital.
Dr. Lougheed has authored over 50 peer-reviewed publications and 2 book chapters. Her research interests include asthma symptom perception, mechanisms of cough in asthma, work-related asthma, asthma health services and outcomes research, and guidelines implementation. She has received funding from CIHR, AllerGen NCE, the Ontario Thoracic Society and two Academic Health Sciences Centre AFP Innovation Fund grants. She has had a major role in many aspects of the provincial asthma strategy, including leading the development, evaluation, and implementation of a standardized care map for management of adults with acute asthma in emergency departments.
Learn more about Dr. Diane Lougheed
|Dr. David Reed
After completing his PhD in physiology at Queen’s University, Dr. Reed completed medical school at the University of Toronto. He then completed his clinical training that included internal medicine at the University of Alberta and gastroenterology at McMaster University. He then pursued a research fellowship at Queen Mary, University of London.
His clinical interest is in gastrointestinal motility disorders. His research interest is how the interaction of luminal factors (e.g. dietary components) with stress or the microbiota modulates pain signaling and motility in disorders such as irritable bowel syndrome.
|Dr. Elaine Petrof
Dr. Petrof is an Associate Professor in the Department of Medicine with a cross-appointment to Microbiology & Immunology /Department of Biomedical and Molecular Sciences. She is also a member of the GIDRU (Gastrointestinal Diseases Research Unit). Her position is one of Clinician Scientist, with 75% protected time for research.
Dr.Petrof joined the Queen’s University Faculty in 2008. She attended the University of Toronto for medical school, and then spent over 10 years in Chicago where she received the rest of her medical and research training. She completed her Infectious Diseases and Clinical Pharmacology fellowships, and her research post-doctoral training on host-microbial interactions & probiotics, at the University of Chicago. Her current research interests include intestinal inflammation and effects of the human gut microbiome on infectious and non-infectious causes of colitis.
Dr.Petrof is particularly interested in recurrent Clostridium difficile infection (CDI) and with her colleagues has initiated a stool transplant study at KGH to treat refractory CDI. Dr.Petrof is investigating the use of a “cleaner”, purified mixture of bacteria derived from healthy donor stool to replace stool transplants for use in patients with recurrent C.difficile infections.
Learn more about Dr. Elaine Petrof
|Dr. Sudeep Gill
Dr. Gill is an Associate Professor in the Division of Geriatric Medicine, with cross-appointment in the Department of Public Health Sciences. His clinical work focuses on Specialized Geriatrics services at Providence Care (inpatient geriatric rehabilitation and outpatient geriatric medicine clinics) and Kingston General Hospital (geriatrics consult service). His undergraduate teaching roles have included Clinical Skills and Critical Enquiry. He helps supervise journal clubs for the core Internal Medicine residents and a joint Geriatric Psychiatry and Geriatric Medicine journal club. He is a Scientist with the Institute for Clinical Evaluative Sciences (ICES). He previously served as Chair of the Providence Care Pharmacy and Therapeutics Committee, and has been a member of the Committee to Evaluate Drugs (CED), an advisory committee to the Ontario Ministry of Health and Long-Term Care on decisions about medications included on the province’s publicly funded formulary. At Queen’s University, he has been a member of Senate Advisory Research Committee (2009-2012), a member of the AHSC AFP Innovation Fund grant application review committee, and a member of the Department of Medicine Promotions Committee.
Learn more about Dr. Sudeep Gill
|Dr. Chris Simpson
Chris Simpson was born in Moncton in 1967 and raised in Nackawic, a small pulp mill town of 1,000 people in western New Brunswick. Torn between pursuing a career in music or medicine, he obtained a BSc at the University of New Brunswick while playing saxophone with The Thomists, a 20-piece big swing band based in Fredericton and well-known across the Atlantic provinces.
He went on to medical school at Dalhousie University in Halifax and obtained his MD in 1992. He subsequently completed internal medicine and cardiology training at Queen’s University in Kingston and then a Heart and Stroke Foundation Clinical and Research Fellowship in Cardiac Electrophysiology at the University of Western Ontario, under the supervision of Dr. George Klein.
After returning to Kingston in 1999, he founded the Heart Rhythm Program at Kingston General Hospital, establishing catheter ablation and implantable defibrillator programs. From 2006-2016 he served as Professor and Head of Cardiology at Queen’s University, as well as Medical Director of the Cardiac Programs at Kingston General Hospital/Hotel Dieu Hospital. Currently, he is Vice-Dean (Clinical) and Medical Director of the Southeastern Ontario Academic Medical Organization (SEAMO) in the Queen’s School of Medicine. He is also an Affiliate Scientist with the Institute for Clinical Evaluative Sciences (ICES-Queen’s) and a member of the Queen’s School of Policy Studies Health Policy Council.
Dr. Simpson’s primary non-clinical professional interest is health policy – particularly access to care, seniors’ care, wait times and medical fitness to drive. He served as the chair of the Wait Time Alliance (WTA) – a federation of 17 medical specialty societies and the Canadian Medical Association (CMA) – and is a past chair of the Canadian Cardiovascular Society’s (CCS) Standing Committee on Health Policy and Advocacy. He serves on the Cardiac Care Network of Ontario Board of Directors, is a past member of the CCS executive and a former governor of the American College of Cardiology. He currently serves as the Canadian representative to the World Medical Association (WMA).
He served as the first president of the Canadian Heart Rhythm Society – the national association of heart rhythm specialists and allied health professionals. Over the years he has served on numerous editorial boards and advisory committees, and has chaired or been a member of several national consensus conferences and guidelines statements, including the CCS Consensus Conference on Medical Fitness to Drive and Fly, of which he was co-chair. He is a co-editor of the CMA Driver’s Guide. He was the first recipient of the CMA Award for Young Leaders.
He served as the 2014-2015 President of the Canadian Medical Association (CMA), during which he championed seniors’ care and helped to guide the profession on the issues of medical aid in dying (MAID) and medical marijuana. In 2015, Dr. Simpson was elected to fellowship in the Canadian Academy of Health Sciences and currently serves on their Board of Directors.
An active clinician, educator and researcher, Dr. Simpson has authored or co-authored over 350 peer reviewed papers and abstracts and has won numerous teaching awards. His clinical and research interests include access to care and medical wait times, medical fitness to drive, atrial fibrillation, sudden death in the young, catheter ablation and cardiac resynchronization therapy.
Outside medicine, Dr. Simpson serves on the Board of Directors of Cantabile Choirs of Kingston and is a proud supporter of University Hospitals Kingston Foundation. He recently served as Chair of the Kingston Blue Marlins Swim Team Board of Directors. The proud father of three daughters and a son, he immensely enjoys watching and cheering their academic, musical and athletic pursuits.
Learn more about Dr. Chris Simpson
|Dr. Denis O'Donnell
Denis E. O’Donnell, MB, BCh., (NUI), MD (NUI), FRCP(I), FRCP(C) is a Professor of Medicine, with cross appointments to the Departments of Biomedical & Molecular Sciences (Physiology), Rehabilitation Medicine and Kinesiology & Health Studies, Queen’s University, Kingston, Ontario, Canada. He is a Clinician Scientist and past Chair of the Division of Respiratory and Critical Care Medicine and Director of the Respiratory Investigation Unit at Queen’s. He completed clinical research fellowships in Respirology at TrinityCollege, Dublin, and at the University of Manitoba (1984-1988), where he completed a doctoral thesis in medicine on the topic “Mechanisms of Dyspnea in COPD” in 1988. Dr. O’Donnell’s main research focus is clinical integrative physiology and specifically, exercise pathophysiology and mechanisms and management of dyspnea in respiratory disorders. His main clinical focus is COPD and pulmonary rehabilitation.
Dr. O’Donnell had a leadership role (Chair) in the development of best practice guidelines for the management of COPD in Canada. He has been a senior author in over 260 scientific publications. He has co-edited a book on Dyspnea, now in its third edition. He has lectured extensively on these topics both at a national and international level.
He has been the recipient of the Basmajian award for Excellence in Biomedical research at Queen’s University. He held a Career Scientist Award from the Ontario Ministry of Health from 1994 to 2004. He gave the American College of Chest Physicians Distinguished Scientist Honour Lecture in 2005, the Trudeau Lecture for the New York Thoracic Society in 2007, the Jean Jacques Gauthier Award and Honour Lecture, University of Montreal and the John Rankin Visiting Professor and Honour Lecture, University of Madison, Wisconsin in 2008. In 2012 he received an award for Excellence in Research in Respiratory Physiology by the Association for Respiratory Technology & Physiology (ARTP) in the United Kingdom.
He serves on several national and international scientific panels on respiratory diseases and sits on the Editorial Boards for CHEST, Journal of Applied Physiology, Journal of COPD, the International Journal of COPD, and is an Associate Editor of the Canadian Respiratory Journal. He is the Past President of the Canadian Thoracic Society and is a member of the Institute Advisory Board (IAB) for the Canadian Institutes of Health Research (Circulatory and Respiratory Health). He is currently the National Canadian Delegate for the European Respiratory Society.
|Dr. Damian Redfearn
Dr. Damian Redfearn is a CIHR funded clinician-scientist in the Department of Medicine and Division of Cardiology at Queen's University, with an impressive academic record of over 180 peer-reviewed career publications and conference abstracts. The duality of his training as a cardiac electrophysiologist and computational scientist has been instrumental in his successes to date, as it encourages clinical applicability of Dr. Redfearn's research results and accelerates the evaluation of new computational approaches and algorithms to target non-traditional sources in the heart that underpin complex cardiac arrhythmias. The uniqueness of his academic and clinical background allows Dr. Redfearn to inform the direction and growth of his research on the basis of his own clinical experiences in treating patients with the complex arrhythmias atrial fibrillation and ventricular tachycardia.
Learn more about Dr. Damian Redfearn
|Dr. Bill Paterson
Dr. Paterson received his MD from Queen’s University in 1979 and subsequently trained in Internal Medicine at Queen’s and the University of Western Ontario. Following a clinical GI fellowship at Queen’s, he was awarded an MRC Research Fellowship to study esophageal physiology under the mentorship of Dr Raj Goyal at Harvard University. He returned to a faculty position at Queen’s in 1986, where he is currently Professor in the Departments of Medicine and Biomedical and Molecular Sciences. His main clinical and research interests relate to GI motility disorders, with particular emphasis on the pathophysiology of the esophagus. His research program has been funded continuously by MRC/CIHR for 24 years. He holds a Queen’s University Research Chair, is a past President of the Canadian Association of Gastroenterology, and serves on the advisory board for the CIHR Institute of Nutrition, Metabolism and Diabetes.
Learn more about Dr. Bill Paterson
|Dr. Ben Glover
Dr. Glover is the chief of the heart rhythm service and assistant professor at Queens University and Kingston Health Sciences Centre. He is also head of the cardiac electrophysiology fellowship program (Royal College of Physicians and Surgeons of Canada Accreditation) and the director of the scientific program committee in the Canadian Heart Rhythm Association as well as being a member of the CPD committee in the Canadian Cardiovascular Society.
He is a fellow of the European Society of Cardiology and Heart Rhythm Society and a member of the Canadian Cardiovascular Society, European Heart Rhythm Association and the Working Group on Cardiac Cellular Electrophysiology of the European Society of Cardiology.
He graduated from Queens University, Belfast (MB BCh BAO) in 1999 and after performing 3 years in internal medicine (MRCP, London, UK 2002) joined the cardiology program in the Royal Victoria Hospital, Belfast. During this time he performed two years of research looking at various aspects of internal and transthoracic cardioversion for the treatment of atrial fibrillation. Following the submission of his thesis he gained his Doctorate of Medicine from the Queens University in 2006. As a result of this research he was awarded the Purce Calvert Medal, the British Junior Cardiology Association-Cordis International Research Awards for Invasive Cardiology, the Northern Ireland Chest Heart and Stroke prize and the Northern Ireland Healthcare Award for the innovative use of technology to improve Patient Care.
He spent several more years training in general cardiology and subsequently subspecialized in cardiac electrophysiology in Toronto General Hospital, Ontario where he trained in catheter ablations and device therapy as well as publishing data from the Epistry Registry on the use of antiarrhythmic drugs in the management of out of hospital cardiac arrest. He was also awarded an unrestricted research grant examining the use of anti-arrhythmic drugs in the management of ventricular arrhythmias.
As well as publishing in most major cardiology and cardiac electrophysiology journals he has co-authored two books ‘A Clinical Approach to Cardiac Arrhythmia (NSHI, 2011)’ and ‘A Complete Clinical Handbook of Cardiac Electrophysiology’ (Springer 2016) with Pedro Brugada and contributed to several others in the field of cardiac electrophysiology. He is the principal investigator on the “AF ED” trial; a multicentre trial looking at the reasons why patients with atrial fibrillation attend the emergency department and is actively involved in the recruitment of patients for several multicentre trials
He has a special interest in the management of atrial fibrillation and ventricular arrhythmias and is instrumental in building the complex ablation program in Kingston. He also has a keen interest in teaching and is undertaking a masters in medical education through John Hopkins University, Baltimore.
Learn more about Dr. Ben Glover
|Dr. Adrian Baranchuk
Dr. Adrian Baranchuk, a native of Buenos Aires, Argentina, obtained his MD from the University of Buenos Aires in 1990. After qualifying in Internal Medicine and Cardiology (1995), he completed a Clinical Fellowship in Cardiac Electrophysiology (1997). In 2002 he immigrated to Spain for a Research Fellow. Dr. Baranchuk was appointed as a Clinical Fellow in Electrophysiology at McMaster University in September 2003.
Dr. Baranchuk was appointed as an Assistant Professor of Medicine at Queen’s University (2006), promoted to Associate Professor in 2010 and to Full Professor in 2016 (with Tenure). He has founded the EP Training Program in 2007.
He is a member of numerous editorial boards (Europace, Annals of Noninvasive Electrocardiology, etc) and reviewer of several journals. He is currently the Editor-in-Chief of the Journal of Electrocardiology.
The recipient of a teaching award (Outstanding Contribution in the Core Internal Medicine Program 2009) and 2014 awarded with the prestigious “Faculty of Health Sciences Education Award”.
Dr Baranchuk was awarded with the “Golden Caliper Award” from the SOLAECE (Latin American Society of Pacing and Electrophysiology) for his outstanding contributions to science in 2014 and with the “ISHNE Junior Investigator Award” in April 2015. In 2016 he was distinguished with the “10 Most Influential Hispanic-Canadian Award” from the Hispanic business.ca and TD Bank. He was recently awarded with the “David Ginsburg Mentorship Award” in December 2017.
He has published more than 520 articles in well-recognized international journals (400 in Pubmed), 50 book chapters and presented more than 225 abstracts. He is the President of the International Society of Electrocardiology (ISE) for the period 2017-2019. He is currently serving as Canadian Vice President of the Interamerican Society of Cardiology (2017-2019).
He has mentored more than 100 students and residents and his publications usually include a Med Student or resident as first author. He is the current Director of the Critical Enquiry course at Queen’s University. He has been elected Member of the Electrophysiology Section Leadership Council of the American College of Cardiology (2017-2020)
He is in charge of organizing the ECG module for the trainee day and the ECG Workshops during the Canadian Cardiovascular Congress. He chairs the Annual Cardiovascular Symposium at Queen’s University.
He lives in Kingston, Ontario, Canada with his wife Barbara and his daughter, Gala.
|Dr. Tara Baetz
Areas of Clinical interest:
Areas of Research Interest:
Learn more about Dr. Tara Baetz
|Dr. Onofre Moran-Mendoza
Dr. Moran-Mendoza has a Master's in Clinical Epidemiology and a PhD in Clinical-Classical Epidemiology.
Currently runs the Tuberculosis Clinic simultaneously with the Infectious Disease Specialists; he also has a General Respirology Clinic and recently started the Interstitial Lung Disease Clinic at Hotel Diue Hospital.
He teaches in several undergraduate courses at the Faculty of Medicine at Queen's University, including the Critical Appraisal course and the General Respirology course; as well as teaches in the Internal Medicine Residency and the Respirology Training programs.
His Research interests are particularly the diagnostic role of tuberculin skin testing in Latent TB Infection and the development of a database for Interstitial Lung Diseases.
Learn more about Dr. Onofre Moran-Mendoza
|Dr. Tassos Anastassiades
Dr. Tassos Anastassiades is a Clinician Scientist and an Emeritus Professor of Medicine. His clinical training was at McGill at the Royal Victoria Hospital and he did most of his PhD work at the Rockefeller University in New York. He serves as Head of the Division of Rheumatology and has provided local and National leadership in Arthritis for a number of years. His main clinical and teaching interest is currently in osteoporosis.
His Laboratory research is in connective tissue metabolism. The emphasis is on repair of damaged cartilage and bone. He has developed chemically modified glucosamines by changing the N-acetyl group to other moieties. He showed that one of these compounds demonstrated pronounced protective effects on the bones of animal models of destructive arthritis and of osteoporosis. These modified glucosamine compounds can be positioned somewhere between pharmaceuticals and nutriceuticals and appear to have very low toxicity.
Recently his attention has turned to chemically modifying hyaluronic acid, the giant, ubiquitous molecule of connective tissues. Surprisingly, these modified hyaluronic acid compounds, which are of relatively low molecular weight, show a striking ability to reduce the production of pro-inflammatory cytokines. Both the modified glucosamines and hyaluronic acid compounds have potentially multifaceted translational applications.
Dr. Anastassiades is also involved in observational research in osteoporosis and is the Director for the Kingston Centre of the Canadian Multicentre Osteoporosis Study (CaMOS), which is a CIHR-funded initiative now in its 17th year.
|Dr. Christine White
Dr. White completed her BSc (1993) and MSc (1995, cellular and molecular pathology) at the University of Toronto. She graduated with her MD from Queen's University in 1999 and then undertook her Internal Medicine and Nephrology training at the University of Ottawa. She started her faculty appointment at Queen's University as an assistant professor in the Department of Medicine, Division of Nephrology in 2005 and is now an associate professor.
Dr White is a recipient of a SEAMO Clinician Scientist Development Program Award. Her research program focuses on the measurement and estimation of kidney function using conventional and novel markers. She has established a GFR measurement program at Queen's and is the recipient of a CIHR operating grant to develop novel accurate GFR measurement protocols.
She is also the Primary Lead of the Ontario Renal Network-Ontario Health Study Scientific Committee and is the director of the Chronic Kidney Disease Program at Kingston General Hospital.
Learn more about Dr. Christine White
|Dr. Wendy Parulekar
Dr. Parulekar is a graduate of the University of Ottawa Medical School where she also completed residency training in Internal Medicine and Medical Oncology (1996). This was followed by a fellowship in Clinical Pharmacology at the Toronto-Sunnybrook Regional Cancer Centre. Since 1999, she has held a joint clinical/research position at Queen's University. Within the Cancer Clinical Trials division/NCIC CTG, she acts as Senior Investigator for national and international studies in melanoma, as well as carcinoma of the breast, head and neck, and genitourinary system. Other interests include issues relating to clinical trial design and conduct, as well as the challenges and opportunities in clinical trials involving developing nations.
Learn more about Dr. Wendy Parulekar
|Dr. Janet Dancey
Dr. Dancey is Director, Clinical Translational Research NCIC Clinical Trials, Program Leader, High Impact Clinical Trials, Ontario Institute for Cancer Research; Chair, Experimental Therapeutics Network, Cancer Care Ontario; and Professor, Department of Oncology, Queen's University.
Among her duties are to coordinate translational research activities for the Canadian Cancer Trials Group and to foster and support translation research in clinical trials across the province of Ontario. Among her National and International activities, Chair, Biomarker Task Force for the Investigational Drug Steering Committee, Cancer Therapy Evaluation Program (CTEP), US National Cancer Institute (US-NCI) and Member of the US-NCI Program for the Assessment of Clinical Cancer Tests. Prior to joining the Canadian Cancer Trials Group, Dr. Dancey was Associate Chief, Investigational Drug Branch, CTEP, US-NCI where she coordinated the development of over 200 phase 1-3 trials of experimental therapeutics, including trials of novel targeted agent combinations and biomarker studies. Dr. Dancey received her MD (Magna cum Laude) from the University of Ottawa and completed her residency training in internal medicine and medical oncology at the University of Toronto. In 1994-95, she was a research fellow with the Canadian Cancer Trials Group and continued her fellowship training at the Institut Gustave Roussy in France. Dr. Dancey has special expertise in new anti-cancer drug development, linking drug and biomarker development, and associated clinical trials methodology. She is the author of co-author of over 100 publications in peer-review journals, 100 abstracts presented at scientific meetings and 15 book chapters. She has been an invited speaker at numerous local, national and international meetings, and has been Chair for development therapeutics and biomarker sessions for ASCO and AACR Annual Meetings, and EORTC-NCI-AACR Molecular Targets Meetings.
|Dr. Michael Brundage
Dr. Michael Brundage is a currently a Professor of Oncology and of Community Health and Epidemiology at Queen's University. Michael's research and teaching interests link epidemiological methods in clinical trials with clinical practice, including major research programs in applied health-related quality of life research, and in the evaluation of quality of care. His current research interests include health services research related to appropriate access to quality care in radiotherapy, as well as clinical trials methodology and quality of life outcomes in clinical practice. He is currently supported by a senior research chair from Cancer Care Ontario, Canada.
He is presently Director of the Division of Cancer Care and Epidemiology research unit at the Queen's Cancer Research Institute at Kingston, and has a clinical practice at the Cancer Centre of Southeastern Ontario at the Kingston General Hospital. He was formerly the medical director of the CCSEO radiation oncology program, and uses this experience in creating a health services research agenda that is integrated with the CCO provincial programs. He serves on the Canadian Cancer Society Research Institute Advisory Committee on Research, co-chairs the Canadian Cancer Trials Group quality of life research committee, serves on the Board of the International Society for Quality of Life Research, and co-chairs the Prostate Cancer Disease Pathway Management Program at Cancer Care Ontario
Learn more about Dr. Michael Brundage